Beyond pericarditis and myocarditis,
$CRDL is tackling one of healthcare's biggest challenges: heart failure. Its next-gen formulation, CRD-38, is being accelerated to target this $30B market, with its U.S. patent protection now secured to 2040.
#HeartFailure #PlatformTech #Biotech #CRDL